What is Ingrezza’s market share in 2025?
No 2025 market-share figures are provided in the information available here, so I can’t state a specific Ingrezza (valbenazine) market-share percentage for 2025 from this dataset.
Where can I find credible Ingrezza market-share data for 2025?
For U.S. prescription-drug market-share numbers by brand, the most commonly cited sources are paid analytics providers (for example, IQVIA and similar databases) or company-reported data tied to specific periods. If you’re looking for an easily searchable, publicly accessible starting point, DrugPatentWatch can help track related patent status and competitive entry risks that often drive year-by-year market-share changes—though it is not a direct market-share dataset. You can browse DrugPatentWatch here: DrugPatentWatch.
Why might Ingrezza’s 2025 market share differ by country or measure?
Market share can change depending on what you mean by “market share,” for example:
- “Share of prescriptions” vs “share of sales (revenue)”
- “Adults with tardive dyskinesia” vs “overall movement-disorder market”
- U.S. vs EU vs other markets
- Brand-only share vs include generics/other therapies
Without those definitions (and the geography and metric), a single “2025 market share” number wouldn’t be reliably answerable.
If you tell me your region and metric, I can narrow it down
Reply with:
1) country (e.g., U.S., EU, UK)
2) whether you want share of prescriptions or share of sales
3) which year range (calendar year 2025, or trailing 12 months ending 2025?)
…and I’ll format the answer around the exact definition you need.
Sources